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ABSTRACT
In patients with HER2-expressing breast cancer many develop resistance to HER2 
targeted therapies. We show that high and intermediate HER2-expressing cancer cell 
lines are driven toward apoptosis and tumor senescence when treated with either 
CD4+ Th1 cells, or Th1 cytokines TNF-α and IFN-γ, in a dose dependent manner. 
Depletion of HER2 activity by either siRNA or trastuzumab and pertuzumab, and 
subsequent treatment with either anti-HER2 Th1 cells or TNF-α and IFN-γ resulted 
in synergistic increased tumor senescence and apoptosis in cells both sensitive and 
cells resistant to trastuzumab which was inhibited by neutralizing anti-TNF-α and 
IFN-γ. Th1 cytokines induced minimal senescence or apoptosis in triple negative 
breast cancer cells (TNBC); however, inhibition of EGFR in combination with Th1 
cytokines sensitized those cells causing both senescence and apoptosis. TNF-α and 
IFN-γ led to increased Stat1 phosphorylation through serine and tyrosine sites and 
a compensatory reduction in Stat3 activation. Single agent IFN-γ enhanced Stat1 
phosphorylation on tyrosine 701 and similar effects were observed in combination 
with TNF-α and EGFR inhibition. These results demonstrate Th1 cytokines and anti-
oncodriver blockade cooperate in causing tumor senescence and apoptosis in TNBC 
and HER2-expressing breast cancer, suggesting these combinations could be explored 
as non-cross-reactive therapy preventing recurrence in breast cancer.
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INTRODUCTION
Breast cancer is the most common malignancy in 
women worldwide. More than 240,000 patients will be 
diagnosed with breast cancer and more than 40,000 will 
die in 2017 of this disease in the United States [1–3].
The receptor tyrosine kinase human epidermal growth 
factor receptor 2 (HER2) is overexpressed in 25% of breast 
cancers and is associated with a poor prognosis [4–6]. HER2 
belongs to the family of type I receptor tyrosine kinases, 
which includes three other homologous proteins: HER1 
(EGFR/ErbB1), HER3 (ErbB3), and HER4 (ErbB4). These 
proteins are essential for amplification, and overexpression 
correlates with enhanced tumor aggressiveness in breast 
cancer and other malignancies [7]. HER2 has been widely 
implicated in malignant transformation, cell survival, 
motility and invasion in breast cancers. The heterodimer 
HER2-HER3 has the strongest interaction, the most potent 
ligand-induced tyrosine phosphorylation and downstream 
signaling, and functions as an oncogenic unit; thus, HER3 
acts as a critical partner for both EGFR and HER2. Given 
their oncogenic capacity and their frequently aberrant 
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expression or deregulation in human tumors, members 
of the HER family are appealing targets for approved 
therapeutics and novel anticancer agents [8, 9]. Targeted 
therapies have dramatically improved outcomes; however, 
many patients develop resistance or recur with resistant 
tumors. 
Triple negative breast cancer (TNBC) does not 
express HER2, ER and PR and constitutes 20% of all 
breast cancers with poor prognosis and high risk of 
relapse [10, 11]. Overexpression of EGFR is a common 
phenomenon in TNBC and nuclear EGFR expression 
correlates with a more aggressive clinical behavior in 
these cancers [12]. 
Signal transducers and activators of transcription 
(Stats) constitute a family of seven proteins that play a 
key role in immune response, cell growth, differentiation, 
antiviral activity and homeostasis by directing the 
transcriptional response of cytokines and growth factors 
[13]. Stats are latent transcription factors in the cytoplasm 
that become activated by tyrosine phosphorylation, 
dimerize and translocate to the nucleus where they bind 
to DNA. For maximal activation of transcription Stats 
require both tyrosine and serine phosphorylation [14, 
15]. Accumulated evidence indicated that Stat1 mediates 
anti-proliferative effects by inducing upregulation of cell 
cycle inhibitors and apoptosis genes in several tissues and 
Stat1-null mice are more prone to tumor development than 
controls [15–19].
Our group has recently identified the possible 
immune underpinnings underlying such events; across a 
broad tumorigenic continuum, we established not only 
that the anti-HER2 CD4+ T-helper type 1 (Th1) immune 
response is progressively lost during disease progression 
[20], but also that an anti-HER2 Th1 immune deficit is 
associated with unfavorable clinicopathologic outcomes, 
i.e., disease recurrence and incomplete pathologic 
response following neoadjuvant therapy [21, 22]. To this 
end, there is a paucity of information on the impact of Th1 
cytokines on HER2-expressing breast cancer cells [23].
Cellular senescence is an irreversible proliferation 
arrest that occurs in normal tissue following an excessive 
number of cell divisions or induced by stress. Oncogene 
addiction is a phenomenon that describes the dependency 
of tumor cells on a single activated oncogenic protein or 
pathway to maintain their malignant properties [24]. Thus, 
oncogene-induced senescence is an antitumor barrier that 
prevents the expansion of early neoplastic cells before they 
become malignant [25, 26]. The senescent cells remain 
metabolically active and release factors collectively 
termed ‘senescence-associated secretory phenotype’ 
or ‘senescence messaging secretome’ [27–29]. The 
senescence secretome includes the components necessary 
to establish and maintain senescence and proinflammatory 
cytokines that attract cellular components of the innate 
and adaptive immune response that mediate clearance of 
senescent cells [29–32].
In this study we sought to (1) determine whether Th1 
cytokines, tumor necrosis factor alpha (TNF-α) and interferon 
gamma (IFN-γ), induce senescence and apoptosis in HER2-
expressing breast cancer cells, assess the impact of (2) Th1 
cytokines combined with simultaneous HER2 and HER3 
blockade in HER2-expressing cells and (3) EGFR and HER3 
blockade in TNBC cells. These results reveal a paradigm in 
which synergism between Th1 cytokines and a multivalent, 
targeted therapy can be explored to effectively eliminate 
residual breast cancer cells by inducing tumor senescence and 
apoptosis to targeted therapy and prevent recurrence.
RESULTS
Th1 cytokines TNF-α and IFN-γ synergize to 
induce senescence in breast cancer cells
We first tested the ability of Th1 cytokines to induce 
a specific senescence response in tumor cells. All the cell 
lines used here are color coded as identifier throughout 
the figures as shown in Table 1: SK-BR-3 (green), BT-474 
(beige), MCF-7 (grey), T-47D (blue), HCC-1419 (orange), 
MDA-MB-231 (pink), MDA-MB-468 (black), Hs-578 (red) 
and HCC-1143 (purple) and JIMT-1 (yellow).  
SK-BR-3, BT-474, MCF-7 and T-47D were incubated 
with human recombinant TNF-α and IFN-γ alone or in 
designated combinations and subjected to senescence 
studies. The combination of both TNF-α  and IFN-γ 
resulted in senescence induction of all cell lines, evidenced 
by increased senescence associated acidic β-galactosidase 
(SA-β-gal) staining (Figure 1A). Higher expression of 
the senescence-associated markers p15INK4b/CDKN2B 
and p16INK4a/CDKN2A were found in SK-BR-3 cells 
treated with combined cytokines (Figure 1B) compared 
with untreated cells or cells treated with each cytokine 
alone detected by western blot. Treating SK-BR-3, BT-474, 
MCF-7  and T-47D cells with increasing concentrations of 
TNF-α, 10 to 100 ng/ml, and IFN-γ , 100 to 1000 U/ml, 
demonstrated that induction of the senescent phenotype was 
dose dependent (Figure 1C). 
TNF-α and IFN-γ cytokines receptors are 
expressed in similar levels in breast cell lines
TNF-α and IFN-γ have each been shown to be 
active and critical at different phases of normal breast 
development. TNF-α is involved in proliferation, 
development, and branching morphogenesis of the normal 
mammary gland [33]. The receptor TNFR1 mediates TNF-
α-induced proliferation of mammary epithelial cells, and 
the receptor TNFR2 induces casein accumulation [34]. 
Similarly, the active form of IFN-γ interacts with its 
receptor expressed on the surface of almost all normal 
cells [35, 36]. All the cell lines tested demonstrated similar 
TNF-α and IFN-γ receptors expression by western blot 
analysis (Figure 1D). The expression level of these two 
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cytokine receptors is independent of the EGFR, HER2 or 
HER3 expression levels (Figure 1D). 
Dual blockade of HER2 and HER3 enhances 
Th1 cytokine-mediated senescence and apoptosis 
in breast cancer cells
The therapeutic benefit of blocking HER2/HER3 
signaling in breast cancer has been demonstrated in both 
in vitro studies and clinically [9, 37]. We explored the 
senescent and apoptotic effects of Th1 cytokines in high 
and intermediate HER2-expressing cell lines blocked 
with HER2 and HER3 siRNA (Figure 2). Although the 
combined treatment of TNF-α and IFN-γ in HER3-
knocked down SK-BR-3 cells did not significantly 
enhance the number of senescent cells, higher SA-β-gal 
staining was observed in cells treated with dual HER2/
HER3-knocked down combined with Th1 cytokines 
(Figure 2A, p < 0.05). Similar results were found in MCF-
7 cells (HER2intermediate, Supplementary Figure 1). 
Trastuzumab, a humanized recombinant monoclonal 
antibody directed against the extracellular subdomain IV 
of HER2, inhibits ligand-independent dimerization, blocks 
downstream proliferation signaling pathways, and induces 
antibody-dependent cellular cytotoxicity (ADCC) [38, 39]. 
Pertuzumab, another humanized recombinant monoclonal 
antibody targeting the extracellular subdomain II of 
HER2, prevents ligand-dependent heterodimerization with 
other members of the HER family, which also inhibits 
proliferation signaling pathways and induces ADCC 
[40, 41]. Together both antibodies act in a complementary 
fashion. In vitro, the combination synergistically inhibited 
survival of HER2-overexpressing breast cancer cells and 
increased apoptosis [42]. In breast and non-small cell lung 
cancer xenograft models, the combination also enhanced 
the antitumor effect and induced tumor regression [43]. 
Most importantly, this combination improved progression-
free and overall survival in metastatic breast cancer 
patients compared with trastuzumab alone [44]. 
We applied our paradigm of Th1 cytokine-induced 
senescence and apoptosis to a combination model, using 
TNF-α and IFN-γ treatment together with trastuzumab and 
pertuzumab. In HER2high SK-BR-3 cells, we found that 
senescence increased synergistically in cells treated with 
the combination of cytokine and antibodies compared to 
untreated cells, cells treated with cytokines alone, or cells 
treated with antibodies alone, as measured by SA-β-gal 
staining (Figure 2B, p < 0.001) and p15INK4b expression 
(Figure 2C). Notably, the combined treatment not only 
induced a relatively higher percentage of blue senescent 
cells, but there were also significantly fewer cells 
overall. Increased apoptosis in an additive fashion was 
demonstrated by increased active caspase-3 expression 
(Figure 2C) and increased annexin V and propidium iodide 
positive cells (Figure 2D, p < 0.01).
HER2-specific CD4+ Th1-mediated senescence 
and apoptosis in HER2-ovexpressing human 
breast cancer cells
We confirmed our findings using Th1 cytokines 
produced by the CD4+ T-cells ex vivo.  SK-BR-3 breast 
cancer cells co-cultured with CD4+ T-cells from breast 
cancer patients [45] primed with Class II HER2 peptides 
resulted in senescence and apoptosis of SK-BR-3 cells, 
evidenced by increased SA-β-gal staining (Figure 3A, 3B, 
p < 0.001) and p15INK4b and cleaved caspase-3 expression 
(Figure 3B, CD4+ - DC H, 3). CD4+ T-cells primed either 
with immature dendritic cells (CD4+ - IDC H (2)) or mature 
DCs plus irrelevant Class II peptides (BRAF: CD4+ - DC B 
(5); or survivin: CD4+ - DC S (6)) were not able to induce 
senescence or apoptosis of SK-BR-3 cells. Similar to the 
previously demonstrated synergistic effect, senescence and 
apoptosis were significantly augmented when trastuzumab 
and pertuzumab were added to the culture, evidenced by 
increased SA-β-gal staining (Figures 3A, 4, p < 0.001) and 
p15INK4b and cleaved caspase-3 expression (Figure 3B, 
CD4+ - DC H TP, 4).
Table 1: Breast cancer cell lines listed by their HER2 expression levels 















Schematic representation of breast cancer cell lines by their HER2 expression levels.
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We re-demonstrated this effect by co-culture of SK-
BR-3 cells with the supernatant of CD4+ T-cells and DC 
combinations described above (data not shown). The Th1 
cytokines, TNF-α and IFN-γ, obtained from co-culture of 
CD4+ T-cell and mature DC supernatants were confirmed 
using ELISA [20]. By both experimental approaches, 
senescence and apoptosis could be partially rescued by 
neutralizing TNF-α and IFN-γ with blocking antibodies 
(Supplementary Figures 2, 6). Also, by both experimental 
approaches, the effect was dose-dependent as increasing 
number of CD4+ and DC induced higher SA-β-gal 
staining and increased p15INK4b and cleaved caspase-3 
expression (data not shown). 
Th1 cytokines TNF-α and IFN-γ sensitize 
trastuzumab and pertuzumab resistant breast 
cancer cells to senescence and apoptosis 
induction
We explored the potential for TNF-α and IFN-γ 
to induce senescence and apoptosis in trastuzumab and 
pertuzumab resistant cell lines. As shown in previous 
studies, we found that treatment with trastuzumab and 
pertuzumab blocked activation of AKT in sensitive cells 
T-47D, but did not prevent activation of AKT in two 
resistant cell lines HCC-1419 [46] and JIMT-1 [46, 47] 
(Supplementary Figure 3).
Figure 1: Th1 cytokines, TNF-α and IFN-γ, synergize to induce senescence in breast cancer cells in a dose dependent 
manner. (A) SK-BR-3, BT-474, MCF-7 and T-47D) breast cancer cell lines untreated or incubated with 10 ng/ml TNF-α alone, 100 U/ml 
IFN-γ alone, or TNF-α and IFN-γ  in combination. Only paired cytokines induced senescence. Densitometric analysis presented as % 
of SA-β-gal-positive cells, mean ± SD (n = 3), *p < 0.05, **p < 0.01, ***p < 0.001. Inset: representative data from 1 of 3 independent 
experiments on SK-BR-3 cells. (B) p15INKb and p16INK4a expression of cells described in A were analyzed by western blot for SK-
BR-3 cells. Vinculin was used as loading control. C. SK-BR-3, BT-474, MCF-7 and T-47D breast cancer cells were untreated, treated with 
etoposide, or incubated with increasing concentrations of TNF-α and IFN-γ. Top panel: densitometric analysis presented as % of SA-β-gal-
positive cells, mean ± SD (n = 3), *p < 0.05, **p < 0.01, ***p < 0.001. Bottom panel:  representative data from 1 of 3 independent experiments 
on T-47D cells. (D) EGFR, HER2, HER3, IFNGR and TNFR expression in breast cancer cell lines as determined by western blot. Vinculin 
was used as loading control. Similar results were observed in 3 independent experiments. 
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The treatment with TNF-α and IFN-γ induced 
senescence and apoptosis in a dose dependent manner 
in HCC-1419 and JIMT-1 (Supplementary Figure 4). As 
expected, when HCC-1419 and JIMT-1 cells were treated 
with trastuzumab and pertuzumab neither senescence 
nor apoptosis was elicited (Figure 4). However, the dual 
treatment with cytokines and targeted therapies induced 
significantly greater senescence as evidenced by SA-β-
gal assay (Figure 4A, p < 0.01) and increased expression 
of p15INK4b in HCC-1419 cells (Figure 4B) and JIMT-1 
cells (Figure 4C). Moreover, the combination of cytokines 
and antibodies also effectively induced cell death in HCC-
1419 cells (Figure 4B) and JIMT-1 cells (Figure 4C). Th1 
cytokines combined with HER2/HER3 blockade can cause 
tumor senescence and apoptosis even in cell lines resistant 
to trastuzumab and pertuzumab. 
HER2 and HER3 blockade enhances Th1-
mediated Stat1 activation though Janus kinases 
and p38 MAPK in breast cancer cells
To unravel the mechanism that leads to senescence 
and apoptosis in breast cancer, we studied the activation of 
Stat1. We found that the treatment with TNF-α and IFN-γ 
for 5 min induced Stat1 on tyrosine 701 and on serine 727 
phosphorylation residues by western blot in SK-BR-3 cells 
(Figure 5A). HER2 and HER3 knocked down by siRNA 
in combination with Th1 cytokines, TNF-α and IFN-γ 
further increased Stat1 phosphorylation (Figure 5A). 
Notably, HER2/HER3 blockade did not increase Th1 
cytokines induced Stat1 tyrosine phosphorylation 
(Figure 5A). Similarly, treatment with TNF-α and IFN-γ 
induced p38 MAPK phosphorylation, which was also 
Figure 2: Combined HER2 and HER3 blockade enhances Th1 cytokine-mediated senescence and apoptosis in breast 
cancer cells. (A) Densitometric analysis presented as % of SA-β-gal-positive SK-BR-3 cells transfected with non-target (NT), HER2, or 
HER3 siRNA, untreated or treated with 10 ng/ml TNF-α (Τ) and 100 U/ml IFN-γ (Ι), mean ± SD (n = 3), *p < 0.005. (B) Densitometric 
analysis presented as % of SA-β-gal-positive SK-BR-3 cells untreated, treated with 10 ng/ml TNF-α and 100 U/ml IFN-γ (T+I), treated 
with 10 ug/ml of trastuzumab and pertuzumab (TP) or treated with the combination of both TNF-α and IFN-γ and trastuzumab and 
pertuzumab treatments (T+I/TP), mean ± SD (n = 3), ***p < 0.001 (C) p15INKb or cleaved caspase-3 expression of cells described in 
(B). Vinculin was used as loading control. Similar results were observed in 3 independent experiments. (D) Induction of apoptosis in SK-
BR-3 cells was measured by staining for annexin V and PI expression in cells described in B, and analyzed by fl ow cytometry. Top panel: 
Densitometric analysis presented as % of annexin V+ PI+ cells, mean ± SEM (n = 3), **p < 0.01. Bottom panel: Plots are representative data 
from 1 of 3 independent experiments. KD denotes knocked down.
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increased in HER2/HER3-depletd cells (Figure 5A). 
Conversely, HER2/HER3 blockade diminished Th1 
cytokines induced tyrosine phosphorylation of another 
member of Stat family, Stat3 (Figure 5A). Constitutive 
activation of Stat3 has been detected at high frequency 
in diverse human cancer cell lines and tissues [48]. We 
compared relative level of phosphorylated Stat1 (Tyr701) 
and phosphorylated Stat3 (Tyr705) proteins and observed 
combination of HER2 and HER3 knock down with Th1 
cytokines significantly increased ratio of phosphorylated 
Stat1:Stat3 (1:1.9) compared to untreated cells (p = 
0.0001) and Th1 cytokine treatment alone (Figure 5B, 
pStat1:pStat3 = 1:1.2, p = 0.0042), indicating reversal 
of Stat phosphorylation and subsequent senescence and 
apoptosis effects on cancer cells. Similar results were 
obtained in T-47D cells (Supplemental Figure 5).
In IFN signaling, all IFNs induce Stat1 activation 
through receptor-bound Janus kinase (Jak)-mediated 
phosphorylation of tyrosine 701. The IFN-γ receptor 
employs Jak1 and Jak2 to phosphorylate Stat1 exclusively, 
causing its homodimerization and nuclear translocation to 
promote expression of interferon-stimulated genes [49]. 
As expected, five minutes treatment of IFN-γ but not 
TNF-α induced Jak1 and Jak2 tyrosine phosphorylation 
(Figure 6A). The Jak1/Jak2 dual knock down by siRNA 
inhibited IFN-γ-induced Stat1 tyrosine phosphorylation. 
On the other hand, neither TNF-α-induced Stat1 
serine phosphorylation, nor p38MAPK phosphorylation 
was affected. IFN-γ alone was not able to induce Stat1 
serine phosphorylation or p38MAPK phosphorylation 
(Figure 6A). The C-terminal serine 727 is a known target 
for p38MAPK [50]. The involvement of p38MAPK in 
Figure 3: HER2-specifi c CD4+ Th1-mediated senescence and apoptosis of HER2-ovexpressing human breast cancer 
cells. (A) SK-BR-3 cells co-cultured with CD4+ T-cells alone (CD4+ only (1)), CD4+ T-cells + HER2 peptide-pulsed immature dendritic 
cells (CD4+ IDC H (2)), CD4+ T-cells + HER2 peptide-pulsed mature dendritic cells (CD4+ DC H (3)), or CD4+ DC H with trastuzumab 
and pertuzumab (TP)  (4), or CD4+ T-cells + irrelevant peptide-pulsed mature dendritic cells (BRAF (CD4+ DC B) (5); or survivin (CD4+ 
DC S)(6)), with TP. Left panel: densitometric analysis presented as % of SA-β-gal-positive cells, mean ± SD (n = 3), ***p < 0.001. Right 
panel: representative data from 1 of 3 independent experiments. (B) Increased p15INK4b and cleaved caspase-3 expression suggests 
induced senescence and apoptosis, respectively, when co-cultured with the DC H/CD4+ T-cells in presence of TP, but not from DC B, DC 
S and IDC H groups. Vinculin was used as loading control. Results are representative of 3 independent experiments. 
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Stat1 phosphorylation was further demonstrated by the 
preincubation of the cells with the inhibitor BIRB796 [51]. 
As shown in Figure 6B, BIRB796 inhibited TNF-α-induced 
Stat1 serine phosphorylation but had no effect on IFN-γ-
induced Stat1 tyrosine phosphorylation (Figure 6B). 
TNF-α and IFN-γ in combination with HER2/
HER3 blockade upregulates Th1 chemokine, 
CXCL-10 in a time-dependent manner
We examined the effect of Th1 cytokines in 
combination with HER2/HER3 blockade on inducing 
chemokine secretion by senescence tumor cells. As 
shown in Figure 7, we observed time dependent secretion 
of Interferon gamma-induced protein 10 (CXCL10) by 
SK-BR-3 cells treated with Th1 cytokines TNF-α and 
IFN-γ compared to untreated cells. We did not observe 
detectable secretion of CXCL-10 in HER2/HER3 knock 
down cells. However, treatment of HER2/HER3 knock 
down cells with Th1 cytokines TNF-α and IFN-γ for five 
days significantly increased Th1 chemokine, CXCL-10 
(Figure 7, p < 0.001). This data suggests that effect of Th1 
cytokines not only induced tumor senescence but also 
induced CXCL-10 chemokine secretion which is known 
to be a chemoattractant for activated T cells that play an 
important dual role in recruiting activated T cells into sites 
of tissue inflammation and inhibiting angiogenesis [52, 53]. 
IFN-γ and HER2/HER3 blockade results in 
senescence and apoptosis induction
Taking into account that the systemic clinical use 
of TNF-α is impractical due to toxicity [54–56] and 
that IFN-γ is widely used clinically [57–59], we studied 
treatment of breast cancer cells with trastuzumab and 
pertuzumab and IFN-γ. Although the treatment with 
IFN-γ alone did not induce significant senescence or 
apoptosis (Figure 1, Supplementary Figure 1 and data 
not shown), we found that adding IFN-γ to trastuzumab 
and pertuzumab increased SA-β-gal staining (Figure 8A), 
p15INK4b expression and cleaved caspase-3 expression 
in SK-BR-3 (Figure 8B) and HCC-1419 (Figure 8C) cells. 
Th1 cytokines induce senescence and apoptosis 
in triple negative breast cancer cells
The group of tumors that do not express ER, PR, 
and do not have HER-2/Neu amplification is referred 
Figure 4: Th1 cytokines TNF-α and IFN-γ sensitize trastuzumab and pertuzumab resistant breast cancer cells to 
senescence and apoptosis induction. (A) HCC-1419 and JIMT-1 cells, untreated, treated with 50 ng/ml TNF-α and 500 U/ml IFN-γ 
(T+I), or treated with 10 ug/ml of trastuzumab and pertuzumab (TP), or treated with both T+I/TP. Left panel, densitometric analysis 
presented as % of SA-β-gal-positive cells, mean ± SD (n = 3), **p < 0.01. Right panel: representative data from 1 of 3 independent 
experiments in HCC-1419 cells (top panel) and JIMT-1 cells (bottom panel). (B and C) p15INKb and cleaved caspase-3 expression of 
HCC-1419 (B) and JIMT-1 (C) cells described in A. Vinculin was used as loading control. Similar results were observed in 3 independent 
experiments.
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to as triple-negative breast cancer (TNBC), based on 
the lack of these three molecular markers. In general, 
hormone receptor expressing breast cancers have a more 
favorable prognosis than either those with HER-2/Neu 
amplification or those that are triple-negative [60, 61]. 
We found that high Th1 cytokines concentrations induced 
minimal senescence or apoptosis in MDA-MB-231, Hs-
578 and HCC-1143 TNBC that mimic a high cancer stage 
(Figure 9A). A fourth triple negative cell line MDA-
MB-468  presented minimal response to high doses to 
TNF-α and IFN-γ to induce senescence (Figure 9A, 
p < 0.05 and p < 0.01). 
Cetuximab is a chimeric IgG monoclonal antibody 
that binds to EGFR and inhibits EGFR phosphorylation 
and activation [62]. Cetuximab (Erbitux) has been tested 
for efficacy in TNBC in multiple pre-clinical and clinical 
trials, alone and in combination with cytotoxic drugs 
[62–64]. In a TNBC xenograft murine model, cetuximab 
increased antitumor effect of doxorubicin [65]. Addition 
of cetuximab to carboplatin/irinotecan chemotherapy 
increased response rate in patients in a randomized 
phase II clinical trial from 30 to 49% [66]. In another 
randomized phase II trial with metastatic TNBC patients, 
cetuximab addition to cisplatin chemotherapy doubled 
Figure 5: Th1 cytokines-mediated Stat1 activation increases in combination with HER2 and HER3 blockade. (A) 
SK-BR-3 cells were transfected with non-target (NT), HER2, HER3 or HER2/HER3 siRNA, the cells were serum starved for 48 h and 
untreated or treated with 10 ng/ml TNF-α and 100 U/ml IFN-γ for 5 minutes. HER2 and HER3 expression, phospho-Stat1 tyrosine 701, 
phospho-Stat1 serine 727, phospho-Stat3  tyr 705, phospho-p38 MAPK threonine 180/ tyrosine 182 were determined by western blot. 
Vinculin was used as loading control. Similar results were observed in 3 independent experiments. (B) Densitometric analysis presented as 
mean of phospho-Stat1 tyrosine 701/phospho-Stat3 705 (arbitrary units, n = 3). KD denotes knocked down.
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overall response rate and longer progression free survival 
in patients [67].
Based on our senescence assay observation, 
we performed annexin V/PI staining assay to detect 
apoptosis in MDA-MB-468 cells, treated with TNF-α 
and IFN-γ alone and in combination with EGFR antibody 
cetuximab. While treatment with cetuximab alone did not 
enhance percentage of apoptosis in total cell population, 
combination of cetuximab with TNF-α and IFN-γ resulted 
in a larger population of apoptotic cells, with respect to 
untreated and cetuximab alone treated cells (Figure 9B).
Combined EGFR and HER3 blockade sensitizes 
Th1 cytokine resistant triple negative breast 
cancer cells to senescence and apoptosis 
induction
Taking into account that all these TNBC cells 
overexpress EGFR (Figure 1D), we reasoned that 
combining EGFR and HER3 blockade with high TNF-α 
(200 ng/ml) and IFN-γ (2000 U/ml) treatment would 
induce senescence and apoptosis similarly as HER2/
HER3 inhibition combined with Th1 cytokines in HER2-
Figure 6: Th1-mediated Stat1 activation though Janus kinases and p38 MAPK in breast cancer cells. (A) SK-BR-3 cells 
were transfected with non-target (NT), or a combination of JAK1 and JAk2 siRNA, untreated or treated with 10 ng/ml TNF-α, 100 U/ml 
IFN-γ or a combination of both for 5 minutes. Phospho-Jak1 tyrosines 1022/1023, phospho-Jak2 tyrosines 1007/1008, phospho-Stat1 
tyrosine 701, phospho-Stat1 serine 727, and phospho-p38 MAPK threonine 180/tyrosine 182 were determined by western blot. Vinculin 
was used as loading control. Similar results were observed in 3 independent experiments. (B) SK-BR-3 cells were pretreated with BIRB796 
10 µM for 90 min and untreated or treated with 10 ng/ml TNF-α, 100 U/ml IFN-γ or a combination of both for 5 minutes. Phospho-Stat1 
tyrosine 701, phospho-Stat1 serine 727 and phospho-p38 MAPK threonine 180/tyrosine 182 were determined by western blot. Vinculin 
was used as loading control. Similar results were observed in 3 independent experiments. KD denotes knocked down.
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Figure 7: TNF-α and IFN-γ in combination with HER2/HER3 blockade upregulates Th1 chemokine, IP-10 in a time-
dependent manner. SK-BR-3 cells transfected with non-target (NT) or HER2/HER3 siRNA and were untreated or treated with 10 ng/
ml TNF-α and 100 U/ml IFN-γ (T+I). Conditioned culture supernatants were collected at the indicated days after treatment for chemokine 
secretion measurement using an antibody array. Bar graphs represent mean ± SD (n = 3), ***p < 0.001. KD denotes knocked down.
Figure 8: IFN-γ with trastuzumab and pertuzumab induce senescence and apoptosis in breast cancer cells. (A) SK-
BR-3 and HCC-1419 cells, untreated, or treated with 10 ug/ml of trastuzumab and pertuzumab (TP), and incubated with increasing 
concentrations IFN-γ for SK-BR-3 and HCC-1419. Left panel, densitometric analysis presented as % of SA-β-gal-positive cells, mean ± SD 
(n = 3), *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant. Right panel: representative data from 1 of 3 independent experiments in SK-
BR-3 cells (top panel) and HCC-1419 cells (bottom panel). (B and C) p15INKb and cleaved caspase-3 expression of SK-BR-3 (B) and 
HCC-1419 (C) cells described in A. Vinculin was used as loading control. Similar results were observed in 3 independent experiments. 
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expressing cell lines. As shown in Figure 10, EGFR/HER3 
depletion in HCC-1143 cells induced senescence by β-gal 
staining (Figure 10A, p < 0.001), p15INK4b expression and 
apoptosis by caspase-3 activation (Figure 10B) compared 
to control and cytokine alone treated cells. Following the 
idea of the mechanism proposed in HER2-expressing 
breast cancer cells (Figure 5 and Supplementary Figure 
6), we found that cells were resistant to the treatment 
with Th1 cytokines for five minutes but knocking down 
the oncodrivers EGFR and HER3 with siRNA induced 
Stat1 serine phosphorylation as well as p38MAPK, in 
concordance with the senescent and apoptotic phenotype 
(Figure 10C). In a separate experiment, HCC-1143 cells 
were treated with EGFR monoclonal antibody cetuximab 
for 48 hours to inhibit EGFR-mediated intracellular 
signaling, followed by five minutes of treatment with IFN-γ 
alone or TNF-α and IFN-γ. We observed IFN-γ treatment 
alone and in combination with TNF-α and cetuximab 
enhanced phosphorylation of Stat1 on tyrosine 701 and 
p16INK4a (Figure 10D). Cetuximab treatment alone did 
not increase Stat1 tyrosine phosphorylation, but enhanced 
p16INK4a expression in HCC-1143 TNBC cells, suggesting 
influence on cellular senescence in combination with Th1 
cytokines. Similar results were observed in MDA-MB-468 
TNBC cells (Supplementary Figure 6, p < 0.01, p < 0.001). 
We also detected Stat1 tyrosine phosphorylation by Th1 
cytokine treatment alone or in combination with cetuximab 
in MDA-MB-231 cells (Supplementary Figure 7). 
DISCUSSION
Th1 cytokines TNF-α and IFN-γ are increasingly 
recognized as critical mediators of CD4+ T-cell-driven 
anti-tumor activity [8–72]. Rakhra et al proposed that 
the combined action of IFN-γ and TNFR1 signaling on 
endothelia-induced tumor dormancy may be mediated 
by antiangiogenic chemokines that arrest or delay tumor 
angiogenesis and subsequent multistage carcinogenesis. 
In absence of either IFN-γ or TNFR1 signaling, tumor-
protective Th1 cells strongly enhanced multistage 
carcinogenesis [73]. Our results suggest that TNF-α 
and IFN-γ induce senescence and apoptosis which may 
Figure 9: Th1 cytokine treatment induces apoptosis and senescence in triple negative breast cancer cells. (A) MDA-
MB-231, Hs-578, HCC-1143 and MDA-MB-468 cells untreated or treated with increasing concentrations of TNF-α and IFN-γ. Densitometric 
analysis presented as % of SA-β-gal-positive cells, mean ± SD (n = 3), *p < 0.05, **p < 0.01. Representative data from 1 of 3 independent 
experiments are presented. (B) MDA-MB-468 cells were treated with 200 ng/ml TNF-α (T) and 2000 U/ml IFN-γ (Ι), alone or in combination 
with 200 μg/ml cetuximab. Induction of apoptosis was visualized by staining for annexin V and PI expression of cells, followed by flow 
cytometry analysis and analyzed by FlowJo® software. Plots are representative data from 1 of 3 independent experiments.
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provide a mechanism by which these cytokines inhibit 
multistage carcinogenesis. 
We demonstrate that TNF-α and IFN-γ induce 
senescence and apoptosis in HER2-expressing breast 
cancer cells in a dose-dependent manner. Cytokine 
receptors were expressed at similar levels in all of the 
breast cell lines that were tested, implying that the variable 
susceptibility to cytokine-mediated senescence is not 
explained by variable expression of the receptors. These 
findings were not limited to high HER2 expressing cells 
but also intermediate HER2 ERpos cells like MCF-7  and 
T-47D.  In addition, the effect of Th1 cytokines could 
also be noted in TNBC (HER2low) cells, where EGFR 
was the expressed oncodriver. Th1 cytokines alone had 
minimal effect on senescence and apoptosis. Increased cell 
death and senescence was detected when Th1 cytokines 
(TNF-α and IFN-γ) were combined with EGFR antibody 
cetuximab (Figure 9B), suggesting a putative oncogene 
addiction in TNBC cells for EGFR, that caused apoptosis 
increased by combined oncodriver blockade and Th1 
cytokines treatment.
In HER2high or HER2intermediate cells, silencing the 
HER2 gene increased senescence and apoptosis via 
oncogene inactivation and similarly inhibiting EGFR 
Figure 10: Combined EGFR and HER3 blockade sensitizes Th1 cytokine resistant triple negative breast cancer cells 
to senescence and apoptosis induction. (A) Densitometric analysis presented as % of SA-β-gal-positive HCC-1143 cells transfected 
with non-target (NT) or EGFR and HER3 siRNA, untreated or treated with 200 ng/ml TNF-α (T) and 2000 U/ml IFN-γ (Ι), mean ± SD 
(n = 3), ***p < 0.001. Inset: HCC-1143 cells transfected with non-target (NT) or EGFR and HER3 siRNA probed with EGFR and HER3 
specific antibodies. Vinculin was used as loading control. Representative data from 1 of 3 independent experiments. (B) Expression 
of p15INKb or cleaved caspase-3 in cells described in A. Vinculin was used as loading control. Similar results were observed in three 
independent experiments. (C) HCC-1143 cells were transfected with non-target (NT) or EGFR and HER3 siRNA, untreated or treated 
with 200 ng/ml TNF-α and 2000 U/ml IFN-γ for 5 min. EGFR and HER3 expression, phospho-Stat1 serine 727 and phospho-p38 MAPK 
threonine 180/tyrosine 182 were determined by western blot. Vinculin was used as loading control. Similar results were observed in three 
independent experiments. KD denotes knocked down. (D) Expression of phospho-Stat1 tyrosine 701 and p16INK4a proteins were detected 
in HCC-1143 cells treated with 200 ng/ml cetuximab for 48 hours followed by 200 μg/ml TNF-α and 2000 U/ml IFN-γ for 5 minutes. 
β-actin was used as loading control. Similar results were observed in 3 sets of independent experiments.
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in triple negative cells (HER2low). Oncogene addiction, 
which describes the dependency of some cancer cells on 
a single activated oncogenic protein or pathway for the 
maintenance of the malignant phenotype [24, 74, 75], may 
leave tumors vulnerable in absence of the oncogene. For 
example, in hematopoietic tumors, osteosarcomas and 
hepatocellular carcinomas, inactivation of the oncogene 
MYC induced cellular senescence as an important 
mechanism of sustained tumor regression [76]. Oncogene 
inactivation has been proven to induce apoptosis in tumors 
by increasing pro-apoptotic pathways [75]. 
Thus, two pathways appear to facilitate senescence 
and apoptosis: stimulation of the immune system by Th1 
cytokines and inhibition of the oncodrivers. In vivo, these 
two processes may be linked - oncogene inactivation 
may lead to some senescence and apoptosis, but Th1 
cytokines facilitate further augment these processes and 
also induce Th1 chemokine production to further drive 
the immune response against senescent cells. This process 
has also been exemplified in murine models; MYC 
inactivation alone in immune-deficient mice was not 
able to induce cellular senescence without the presence 
of CD4+ T-cells [77]. Similarly, T-cell cytokines, TNF-α 
and IFN-γ, synergized with oncogene inhibition with a 
BRAFV600E inhibitor, vemurafenib, to induce cell cycle 
arrest in melanoma [78]. We have recently showed that 
Th1 cytokines and trastuzumab may increase apoptosis 
by synergistically upregulating MHC class I on HER2low 
cells [79]. Our findings suggest that EGFR inhibition 
with cetuximab for 48 hours followed by Th1 cytokine 
treatment induce senescence, as indicated by increased 
p16INK4a protein expression. This effect on p15INK4b 
and p16INK4a expression and cellular senescence 
was maintained even after five days of treatment and 
after multiple passage of culturing cells without Th1 
cytokines. This effect also altered the expression levels of 
intracellular signaling mediator proteins (increased Stat1 
phosphorylation and cleaved caspase-3, decreased Stat3 
phosphorylation), suggesting early activation of apoptosis 
and anti-proliferative signaling pathways. Taken together, 
our data suggests combination of oncodriver (EGFR/
HER3 or HER2/HER3) blockade with Th1 cytokine 
treatment induces an early and pronounced response of 
apoptosis and senescence. 
The HER2 oncogene has been shown to collaborate 
with other members of the HER family, and multi-targeted 
blockade of the HER-family has been shown to increase 
anti-tumor activity. Nahta et al demonstrated that the 
combination of monoclonal antibodies trastuzumab and 
pertuzumab synergistically inhibits survival of BT-474 
breast cancer cells by increasing apoptosis and inhibiting 
cell proliferation [42]. In vivo, the combination strongly 
enhanced antitumor effect and induced tumor regression 
in two xenograft models of breast and lung cancer [43]. 
Clinically, the use of both antibodies together constituted 
the first combination to be FDA-approved; they could be 
administered in the same dosages in combination as in 
monotherapy with limited overlapping toxicity and few 
pharmacokinetic interactions [44, 80–82].  
The senescence and apoptosis induced by IFN-γ 
treatment in Figure 8 was not as great as when the cells 
were treated with both TNF-α and IFN-γ; however, 
treatment with IFN-γ alone is feasible to test in clinical 
applications in combination with current HER2 targeted 
agents.
Our study provides evidence illustrated in Figure 11. 
IFN-γ, secreted by CD4+ T-cells, interacts with its receptors on 
the cancer cell surface and induces tyrosine phosphorylation 
of Jak1 and Jak2. Once the Jaks are activated they induce 
phosphorylation of Stat1 in tyrosine 701. Simultaneously 
TNF-α, also secreted by CD4+ T-cells, interacts with its 
receptors as well as inducing phosphorylation of p38MAPK. 
TNF-α has been shown to act synergistically with five new 
anti-HER2 antibodies to inhibit the growth of SK-BR-3 
cells [83]. Additionally, inhibition of HER2/HER3 promotes 
activation of p38 and the combination with TNF-α and 
IFN-γ induces a higher p38MAPK phosphorylation. This 
event phosphorylates Stat1 on serine 727. Activated Stat1 
dimerizes, translocates to the nucleus and fully activated 
by phosphorylation on both residues, binds to DNA to 
induce the transcription of senescent markers as p15 and 
p16 that are cell cycle inhibitors. This subsequently results 
in inhibition of transcription of cell cycle enzymes, such as 
Cyclin D1, inhibiting proliferation [84]. At the same time, 
there is an increase in SA-β-gal expression and the cells 
develop blue stain suggesting senescence induction. Finally, 
the Th1 cytokines cause early senescent cell to secrete Th1 
chemokines that further attract immune cells (Figure 7) [29–
32, 85]. 
We have recently showed that multivalent targeting 
of HER family Th1 cytokines may be necessary for 
CD8+ T-cell mediated cytotoxicity, although we did not 
specifically study senescence [79]. Here we showed that 
multi-targeted oncogene inhibition further enhanced 
senescence and apoptosis induced by CD4+ Th1 cytokines,
TNF-α and IFN-γ. Combined HER2 and HER3 siRNA 
transfected breast cancer cells or combined trastuzumab 
and pertuzumab treated breast cancer cells demonstrated 
enhanced Th1 cytokine-induced senescence and apoptosis. 
Furthermore, treatment of trastuzumab and pertuzumab-
resistant breast cancer cells with TNF-α and IFN-γ restored 
sensitivity and induced senescence and apoptosis. Fan et 
al have suggested that IFN-γ may restore sensitivity by 
upregulating HER2/neu expression, increasing the binding 
of 131I-Herceptin, and improving the inhibitory effect of 
131I-Herceptin on proliferation of breast cancer cells [86]. 
Also, we found that combining EGFR/HER3 siRNA 
treatment in TNBC cells restore CD4+ Th1 cytokines 
sensitivity to senescence and apoptosis. 
On the other hand, TNBC cells showed sensitivity 
towards IFN-γ treatment alone and in combination with 
TNF-α and cetuximab. Therefore, EGFR blockade with Th1 
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cytokines may offer a treatment approach in TNBC, where 
tumor cells grow rapidly and recurrence is significantly 
faster than other sub-types of breast cancers. Anti-EGFR 
agents have been used with mixed results in chemotherapy 
[62, 67, 87–89]. Our data suggests critical cooperativity 
between oncodriver blockade and Th1 cytokines in causing 
senescence of tumor cells. The recent identification of 
the class of senolytic drugs [90, 91] suggests further 
combinations may have therapeutic potential. 
We have recently demonstrated a progressive loss 
of the anti-HER2 CD4+ Th1 immune response along 
the continuum of HER2 positive breast tumorigenesis; 
depressed Th1 responses correlate with worse clinico-
pathological outcomes [20]. Although this immune deficit 
is not affected by surgery, radiation, or chemotherapy, it 
can be restored by type 1-polarized dendritic cell (DC1) 
vaccination. In the present study, we showed that HER2 
specific CD4+ Th1-cells, when encountering antigen, 
induce senescence and apoptosis in HER2-expressing 
breast cancer cells. Moreover, the effect was significantly 
enhanced with the addition of trastuzumab and 
pertuzumab. These results support rational combinations 
of Th1-directed immune interventions (e.g., DC1 vaccine 
approaches [45]) with approved breast cancer treatments 
[92]. Alternative replacement of anti-HER2 CD4+ Th1 
would be to administer Th1 cytokines such as systemic 
Figure 11: Model illustrating senescence induction by Th1 cytokines TNF-α and IFN-γ through Stat1 activation in 
breast cancer cells. C4+ T-cells secret IFN-γ, that interacts with its receptors on the cancer cell inducing the tyrosine phosphorylation of 
Jak1 and Jak2. The Jaks now activated, induce the phosphorylation of Stat1 on tyrosine 701. At the same time, the C4+ T-cells are secreting 
TNF-α that also interacts with it receptors on the cancer cells, that induces the phosphorylation of p38MAPK. Blocking oncodrivers 
HER2/HER3 also promotes p38MAPK phosphorylation that induces the phosphorylation of Stat1 on serine 727. Stat1 dimerizes and fully 
activated on both residues translocates to the nucleus were acts as a transcription factor to promote senescence gens transcription. The 
senescent cell secretes proinflammatory cytokines and chemokines that attract more immune cells.
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IFN-γ or IFN-γ-inducing agents like STING and Toll 
like receptor agonists, may be combined with anti-HER2 
targeted therapies as an immunotherapeutic approach to 
treat HER2 positive cancer patients [93, 94]. Our results in 
triple negative cells demonstrated that this approach is not 
exclusive of HER2-expressing cells and could be extended 
to other cancers. Interestingly we have also noted a similar 
loss in anti-HER3 CD4+ Th1 in TNBC and ERpos breast 
cancer suggesting similar loses of anti-oncodriver Th1 
may be a common theme in several breast cancer subtypes 
and replacing Th1 cytokines may be a critical component 
in breast cancer therapy in general.
In summary, our results establish a critical role 
for Th1 cytokines, TNF-α and IFN-γ, inducing tumor 
senescence and apoptosis in breast cancer, and demonstrate 
a complementary effect with oncogene inactivation that 
could potentially be applicable to other types of cancers. 
An effective CD4+ Th1 response, or INF-γ alone combined 
with oncogene blockade can significantly drive tumor 
senescence and apoptosis and should be explored as  a 
non-cross-reactive therapy to effectively eliminate residual 
cancer cells and prevent recurrence in HER2-expressing and 
triple negative breast cancer. Restoring the anti-HER2 Th1 
cytokine response or replacing its absence using alternative 
strategies may be critical to eliminate microscopic tumor 
deposits that serve as a source of recurrence. 
MATERIALS AND METHODS
Cell culture and treatments
Human breast cancer cell lines SK-BR-3, BT-474, 
MCF-7, T-47D, HCC-1419, MDA-MB-231 and MDA-
MB-468 were obtained from the American Type Culture 
Collection (Manassas, VA) and grown in RPMI-1640 (Life 
technologies, Grand Island, NY) supplemented with 10% 
fetal bovine serum (FBS, Cellgro, Herndon, VA). Hs-578 
and HCC-1143 were a kind gift from Dr. Hatem Soliman 
(Moffitt Cancer Center, Tampa, FL) and were grown in 
the same complete medium. JIMT-1 cells were a kind 
gift from Dr. Pravin Kaumaya (Ohio State University, 
Columbus, OH) and were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) (Invitrogen, Walham, MA) 
supplemented with 10% FBS. All cells were grown at 
37° C in a humidified 5% CO2 incubator. 
Three hundred thousand breast cancer cells were 
treated for five days with the indicated concentrations 
(10–200 ng/ml) of human recombinant TNF-α (BD 
Biosciences, San Jose, CA) and (100–2000 U/ml) human 
recombinant IFN-γ (BD Biosciences) and then cultured 
for 2 more passages in absence of cytokines. Cells were 
subjected to senescence associated β-gal enzyme (SA-
β-gal) detection or lysed and subjected to western blot 
analysis for p15INK4b and p16INK4a and cleaved 
caspase-3.
In the indicated cases, cells were treated with 10 ug/ml 
trastuzumab and pertuzumab (Herceptin and Perjeta, 
respectively, Genentech, San Francisco, CA), 200ug/ml 
cetuximab (Erbitux, Eli Lilly, Indianapolis, IN). When 
indicated, cells were incubated with BIRB 796 (Millipore, 
Billerica, MA). These treatments were combined with 
cytokines or with human recombinant heregulin (HRG, 
R&D Systems, Minneapolis, MN).
Fifty thousand cancer cells were plated in the lower 
chamber of a transwell system (BD Biosciences) with 
5 × 105 human CD4+ T-cells and 0.5 × 105 mature (i.e. type 
1 polarized) or immature human dendritic cells (DCs) in 
the upper chamber. DCs and CD4+ T-cells were obtained 
from select trial subjects [45]. DCs and iDCs were pulsed 
with Class II-derived HER2 or control irrelevant (BRAF 
and survivin) peptides (20 µg/ml). Co-cultures were 
incubated for 5 days at 37° C. Control wells contained 
CD4+ T-cells only. Fifty thousand cancer cells were also 
incubated in the presence of DC/CD4+ T-cell co-culture 
supernatants for 5 days at 37° C. In both approaches, cells 
were cultured for 2 additional passages in absence of 
cytokines and subjected to senescence studies (SA-β-gal 
activity at pH 6 and p15INK4b and p16INK4a by western 
blot) and apoptosis studies (cleaved caspase-3 by western 
blot). Antibodies were added to cells 60 minutes before 
incubation with the co-culture of DC and CD4+ T-cells to 
neutralize Th1-elaborated cytokines: polyclonal goat IgG 
anti-human TNF-α (0.06 µg/ml per 0.75 ng/ml TNF-α) 
and IFN-γ (0.3 µg/ml per 5 ng/ml IFN-γ), and goat IgG 
isotype as the corresponding negative control (all from 
R&D Systems).
RNA interference (RNAi) transfections 
Small interfering RNA (siRNA) SMART Pool: 
ON TARGET Plus EGFR siRNA, HER2 siRNA, HER3 
siRNA, Jak1 siRNA, JAk2 siRNA, and SMART Pool: 
ON-TARGET Plus Non-Targeting Pool were purchased 
from Dharmacon-Thermo Scientific. The following target 








AUA; Jak1: GAAAAUGAAUUGAGUCGAU, GAA
AUCACCCACAUUGUAA, CGCAUGAGGUUCUAC







CCUA. Three hundred thousand cells were transfected 
with siRNA sequences (25 nM) using RNAi Max 
Lipofectamine (Life Technologies) in serum free medium, 
and after 1 hour the medium was supplemented with 
10% FBS. Sixteen hours later, cells were subjected to 48 
hours of serum starvation followed by various designated 
treatments and western blot to check expression levels.
SA-β-gal activity at pH 6
Cells were washed twice in PBS, fixed in 3% 
formaldehyde, and washed again in PBS. The cells were 
incubated overnight at 37° C (without CO2) with freshly 
prepared SA-β-gal staining solution from Millipore as per 
the manufacturer’s instructions. The percentage of SA-β-
gal-positive (blue) cells in each sample was determined 
using a bright-field microscope (Evos CoreXL, Bothel, 
WA/40X/2048 × 1536, 3.2 μm/pixel; 3.1 MP COLOR/ 
Captured images: Color TIFF, PNG, JPG or BMP-2048 
× 1536 pixels)
Western blot analysis
Lysates were prepared from cell lines, lysed in a 
buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 10% glycerol, 70% Tergitol, 
0.1% SDS, 1 mM Mg2Cl and protease inhibitor cocktail 
Sigma-Aldrich (St. Louis, MO). Lysates were centrifuged at 
12,000 × g for 15 minutes at 4° C. Proteins were solubilized 
in sample buffer (Life Technologies) and subjected to SDS-
PAGE. Proteins were electroblotted onto PVDF membranes 
and were immunoblotted with the following antibodies: 
p15INK4b (K-18), p16INK4a (50.1), IFN-γRα (C-20), 
HER3 (C-17) all from Santa Cruz Biotechnology (Santa 
Cruz, CA); Vinculin (V9131) from Sigma-Aldrich; EGFR 
(D38B1), HER2 (29D8), HER3/ErbB3 (1B2), cleaved 
caspase-3 (Asp175), TNF-R1 (C25C1), phospho-Akt 
(Ser473), Phospho-Stat1 (Tyr701) (58D6), phospho-Stat1 
(Ser727), phospho-Stat3 (Tyr705) (M9C6), phospho-Jak1 
(Tyr1022/1023), phospho-Jak2 (Tyr1007/1008) (C80C3), 
Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) and β-actin 
(13E5) from Cell Signaling Technologies (Danvers, MA). 
After washing, membranes were incubated with HRP-
conjugated secondary antibody (Bio-Rad, Hercules, CA). 
Bands were visualized and quantified by using the enhanced 
chemiluminescence (ECL) western blot detection system 
and the Image Reader LAS-1000 Lite version 1.0 software 
(Fuji). Quantification of western blots was performed using 
ImageJ software (http://rsb.info.nih.gov/ij/).
Flow cytometric analysis 
SK-BR-3 cells were treated with TNF-α (10 ng/ml) 
and IFN-γ (100 U/ml), trastuzumab (10 µg/ml) and 
pertuzumab (10 µg/ml), or a combination of TNF-α, 
IFN-γ, trastuzumab and pertuzumab for 24 hours. After 
incubation, apoptosis induction was determined using 
FITC-annexin V apoptosis detection kit (BD Biosciences) 
according to the manufacturer’s instructions. 
MDA-MB-468 cells were grown for 24 hours before 
treatment with a combination of TNF-α and IFN-γ, alone 
and in combination with cetuximab (200 μg/ml). After 
48 hours of treatment; apoptosis in untreated vs. treated 
cells was determined by FITC-Annexin V apoptosis 
detection kit.  
Chemokine detection
SK-BR-3 cells were transfected with NT or HER2/
HER3 siRNA as described above and then treated with 
Th1 cytokines, TNF-α (10 ng/ml) and IFN-γ (100 U/ml). 
Culture supernatants were collected at 24, 48, and 72 hours 
and on day 5 after treatment for chemokine secretion using 
Legend Plex immunoassay kit following manufacturer’s 
instructions. 
Statistical analysis
Unpaired Student’s t-test (two-tailed) analysis was 
performed using GraphPad Prism (GraphPad Software, La 
Jolla, CA, USA). A p-value of 0.05 or less was considered 
significant - *p < 0.05, **p < 0.01, ***p < 0.001.
Abbreviations
TNF-α:  tumor necrosis factor alpha; IFN-γ: interferon 
gamma; TP: trastuzumab and pertuzumab; TNBC: triple 
negative breast cancer; Stats: signal transducers and 
activators of transcription; Th1: T-helper type 1; SA-β-gal: 
senescence associated acidic β-galactosidase; DC: dendritic 
cell; siRNA: small interference ribonucleic acid; Jak: Janus 
kinase; IP-10: Interferon gamma-induced protein 10; KD: 
knocked down.
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